Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: A comprehensive review

Journal of Autoimmunity

Volumn 54, Issue , 2014, Pages 112-117

  Cohen, Irun R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmunity; Immune homunculus; Inflammation; Regulation; TCV; Tumors

Indexed keywords

AUTOANTIGEN; CHAPERONIN 60; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PEPTIDE P277; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HSPD1 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; PDCD1 PROTEIN, HUMAN; PEPTIDE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; DOWN REGULATION; EFFECTOR CELL; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; REVIEW; T CELL VACCINATION; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CHAPERONIN 60; HUMANS; MITOCHONDRIAL PROTEINS; NEOPLASMS; PEPTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; VACCINATION;

EID: 84908492426     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.05.002     Document Type: Review

References (57)

1. Cohen I.R. Tending Adam's garden: evolving the cognitive immune self 2000, Academic Press, London.
2. Ebert R.H. The inflammatory process. Inflammation 1965, Academic Press, New York. B.W. Zweifach, L. Grant, R.T. McCluskey (Eds.).
3. Vodovotz Y. Translational systems biology of inflammation and healing. Wound Repair Regen 2010, 18:3-7.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Poutahidis T., Kleinewietfeld M., Erdman S.E. Gut microbiota and the paradox of cancer immunotherapy. Front Immunol 2014, 5:157.
6. Koren O., Goodrich J.K., Cullender T.C., Spor A., Laitinen K., Bäckhed H.K., et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 2012, 150:470-480.
7. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell 2014, 157:121-141.
8. Baker P.I., Love D.R., Ferguson R. Role of gut microbiota in Crohns disease. Expert Rev Gastroenterol Hepatol 2009, 3:535-546.
9. Lazarus A.H., Semple J.W., Cines D.B. Innate and adaptive immunity in immune thrombocytopenia. Semin Hematol 2013, 50(Suppl.1):S68-S70.
10. Müller N. Immunology of schizophrenia. Neuroimmunomodulation 2014, 21(2-3):109-116.
11. Perniola R., Musco G. The biophysical and biochemical properties of the autoimmune regulator (AIRE) protein. Biochim Biophys Acta 2014, 1842:326-337.
12. Burbelo P.D., Ambatipudi K., Alevizos I. Genome-wide association studies in Sjögren's syndrome: what do the genes tell us about disease pathogenesis?. Autoimmun Rev 2014, 13:756-761.
13. Gan L., O'Hanlon T.P., Gordon A.S., Rider L.G., Miller F.W., Burbelo P.D. Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskelet Disord 2014, 15:67.
14. Forni D., Cagliani R., Pozzoli U., Colleoni M., Riva S., Biasin M., et al. A175 million year history of T cell regulatory molecules reveals widespread selection, with adaptive evolution of disease alleles. Immunity 2013, 38:1129-1141.
15. Cohen I.R. Autoantibody repertoires, natural biomarkers and system controllers. Trends Immunol 2013, 34:620-625.
16. Nishio N., Ito S., Suzuki H., Isobe K. Antibodies to wounded tissue enhance cutaneous wound healing. Immunology 2009, 128:369-380.
17. Schwartz M., Cohen I.R. Autoimmunity can benefit self-maintenance. Immunol Today 2000, 21:265-268.
18. Merbl Y., Zucker-Toledano M., Quintana F.J., Cohen I.R. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. JClin Invest 2007, 117:712-718.
19. Nobrega A., Haury M., Grandien A., Malanchere E., Sundblad A., Coutinho A. Global analysis of antibody repertoires. II. Evidence for specificity, self-selection and the immunological "homunculus" of antibodies in normal serum. Eur J Immunol 1993, 23:2851-2859.
20. Poletaev A.B. The immunological homunculus (immunculus) in normal state and pathology. Biochemistry (Mosc) 2002, 67:600-608.
21. Cohen I.R. The cognitive paradigm and the immunological homunculus. Immunol Today 1992, 13:490-494.
22. Ben-Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981, 11:195-199.
23. Ben-Nun A., Cohen I.R. Spontaneous remission and acquired resistance to autoimmune encephalomyelitis (EAE) are associated with suppression of T cell reactivity: suppressed EAE effector T cells recovered as T cell lines. JImmunol 1982, 128:1450-1457.
24. Cohen I.R., Young D.B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991, 12(4):105-110.
25. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
26. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366:2443-2454.
27. Merbl Y., Itzchak R., Vider-Shalit T., Louzoun Y., Quintana F.J., Vadai E., et al. Asystems immunology approach to the host-tumor interaction: large-scale patterns of natural autoantibodies distinguish healthy and tumor-bearing mice. PLoS One 2009, 4:e6053.
28. Madi A, Bransburg-Zabary S, Maayan-Metzger A, Dar G, Kuint J, Ben-Jacob E, etal. Autoantibody repertoires mark tumor-associated and disease-associated self-antigens and differ in maternal and newborn cord sera and in maternal milk, submitted for publication.
29. Cohen I.R. T-cell vaccination for autoimmune disease: a panorama. Vaccine 2001, 20:706-710.
30. Lider O., Reshef T., Beraud E., Ben-Nun A., Cohen I.R. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988, 239:181-183.
31. Zhang J., Medaer R., Stinissen P., Hafler D., Raus J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993, 261:1451-1454.
32. Lohse A.W., Mor F., Karin N., Cohen I.R. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 1989, 244:820-822.
33. Quintana F.J., Mimran A., Carmi P., Mor F., Cohen I.R. HSP60 as a target of anti-ergotypic regulatory T cells. PLoS One 2008, 3:e4026.
34. Jiang H., Kashleva H., Xu L.X., Forman J., Flaherty L., Pernis B., et al. Tcell vaccination induces T cell receptor Vbeta-specific Qa1-restricted regulatory CD8+ T cells. Proc Natl Acad Sci U S A 1998, 95:4533-4537.
35. Hong J., Zang Y.C., Nie H., Zhang J.Z. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:5024-5029.
36. Vandenbark A.A., Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs 2008, 22:265-273.
37. Chen G., Li N., Zang Y.C., Zhang D., He D., Feng G., et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007, 56:453-463.
38. Karussis D., Shor H., Yachnin J., Lanxner N., Amiel M., Baruch K., et al. Tcell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. PLoS One 2012, 7(12):e50478. 10.1371/journal.pone.0050478.
39. http://www.news-medical.net/news/20111108/FDA-grants-Fast-Track-designation-to-Opexas-Tovaxin-for-treatment-of-SPMS.aspx.
40. Aalberse J.A., Kapitein B., de Roock S., Klein M.R., de Jager W., van der Zee R., et al. Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60). PLoS One 2011, 6(9):e24119. 10.1371/journal.pone.0024119.
41. Elias D., Markovits D., Reshef T., van der Zee R., Cohen I.R. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1990, 87:1576-1580.
42. Tikochinski Y., Elias D., Steeg C., Marcus H., Kantorowitz M., Reshef T., et al. Ashared TCR CDR3 sequence in NOD mouse autoimmune diabetes. Int Immunol 1999, 11:951-956.
43. Elias D., Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet 1994, 343:704-706.
44. Schloot N.C., Cohen I.R. DiaPep277 and immune intervention for treatment of type 1 diabetes. Clin Immunol 2014, 149:307-316.
45. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double- blind, phase II trial. Lancet 2001, 358(9295):1749-1753.
46. Raz I., Zieglar A.G., Linn T., Schernthaner G., Bonnici F., Distiller L.A., et al. Treatment of recent onset type 1 diabetes patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care 2014, 37:1392-1400.
47. Quintana F.J., Cohen I.R. The HSP60 immune system network. Trends Immunol 2011, 32:89-95.
48. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunol Rev 2011, 241:241-259.
49. Gottlieb P., Utz P.J., Robinson W., Steinman L. Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clin Immunol 2013, 149:297-306.
50. Ludvigsson J., Chéramy M., Axelsson S., Pihl M., Akerman L., Casas R. for the clinical GAD-study group in Sweden. GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30 months. Diabetes Metab Res Rev 2013 Dec 3, 10.1002/dmrr.2503.
51. Gershwin M.E., Shoenfeld Y. Abul Abbas: an epitope of scholarship. JAutoimmun 2013, 45:1-6.
52. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. JAutoimmun 2012, 39:117.
53. Mitchell R.N. Learning from rejection: what transplantation teaches us about (other) vascular pathologies. JAutoimmun 2013, 45:80-89.
54. Invernizzi P. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. JAutoimmun 2013, 46:1-6.
55. Arnon R., Sela M. Immunomodulation by the copolymer glatiramer acetate. JMol Recognit 2003, 16:412-421.
56. Maron R., Schechter B., Mancini M., Mahlknecht G., Yarden Y., Sela M. Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A 2013, 110:15389-15394.
57. Arnon R., Ben-Yedidia T. Preclinical efficacy of a virus-like particle-based vaccine against avian influenza H5N1. Future Microbiol 2009, 4:503-505.